Meerut Reporter

Hyperphosphatemia Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

 Breaking News
  • No posts were found

Hyperphosphatemia Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

November 16
21:05 2022
Hyperphosphatemia Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
DelveInsight Business Research LLP
DelveInsight’s “Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Hyperphosphatemia market report provides current treatment practices, emerging drugs, Hyperphosphatemia market share of the individual therapies, and current and forecasted Hyperphosphatemia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Hyperphosphatemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hyperphosphatemia market.

Some of the key facts of the Hyperphosphatemia Market Report:

  • In a large community-based cohort study by McGovern et al. (2013), three groups from an adult cohort of the Quality Improvement in Chronic Kidney Disease (QICKD) cluster randomized trial were followed for 2.5 years: people with normal renal function (n = 24,184), people with CKD stages 1–2 (n = 20,356), and people with CKD stages 3–5 (n = 13,292). Hyperphosphatemia (>1.50 mmol/L) was observed in 12 patients (4.3%) with CDK stages 1–2 and 70 patients (22.4%) with CDK stages 3-5 who had a cardiovascular event (not in the group population). Moreover, in the total population of CDK stages 1–2, 279 patients (1.4%) had hyperphosphatemia while 312 patients (2.3%) of the total population of CDK stages 3–5 had hyperphosphatemia.
  • In the United States, the patients with Stage 3–5 CKD accounted for 2,359,056 in 2021.

The United States, in 2021, accounted for 484,792 prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis. Among EU5 countries, Germany had the highest number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were 55,742 in 2021. Whereas, Spain accounted for the least number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were 23,981 in 2021.

Got queries? Click here to know more about the Hyperphosphatemia Market Landscape

 

 

Hyperphosphatemia Overview

Hyperphosphatemia is a condition characterized by an increase in serum phosphate level above 4.5 mg/100 mL. The condition usually occurs due to a decrement in renal function, commonly among chronic kidney disease (CKD) patients, in which phosphate levels shoot up abnormally high. Hyperphosphatemia does not usually have apparent symptoms. It is more likely that the symptoms of an underlying disease that can cause high phosphate levels, such as uncontrolled diabetes, are spotted first. More commonly, patients report uremic symptoms such as fatigue, shortness of breath, anorexia, nausea, vomiting, and sleep disturbances. If phosphate levels in the blood become too high, it may cause mineral and bone disorders and calcification. Also, hyperphosphatemia complexes serum calcium, decreasing the levels of ionized calcium and triggering PTH release, resulting in secondary hyperparathyroidism; this causes a high bone turnover state, releasing calcium from the bone to normalize the serum calcium level.

Treatment for the condition includes restriction of phosphate intake and administration of phosphate-binding antacids, such as calcium carbonate, which can help normalize the phosphate levels in the blood. Dietary modification or consuming a low-phosphorus diet is also necessary, especially in the case of kidney patients. FDA approved phosphate binder therapies for the treatment of the condition includes Kiklin, Auryxia/ Riona/ Nephoxil and Velphoro/ P-TOL. Hyperphosphatemia is often a complication of CKD. One way to reduce the risk is by slowing kidney damage, i.e. by protecting the kidneys by treating the cause of the kidney disease. Another way to reduce the risk is by eating certain foods and avoiding others. It is recommended that a person with an underlying condition linked to hyperphosphatemia should avoid food items that have the letters PHOS. Additionally, certain natural foods, such as peas, milk, and peanut butter, also contain high phosphorus levels. For people with kidney disease, eating a diet with the right amount of minerals is essential in managing the condition. 

Hyperphosphatemia Epidemiology Insights

 

  • The findings from the National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center (NIDDK) suggests that the overall prevalence of CKD increased from 12% to 14% between 1988 and 1994 and from 1999 to 2004 but has remained relatively stable since 2004. 
  • Rastogi et al. (2021) provided strategies to control hyperphosphatemia based on a systematic literature review of clinical trial and real-world observational data on phosphorus control in hemodialysis patients with CKD-mineral bone disorder (CKD-MBD). The study stated that although less than 5% of people with normal kidney function or those in CKD stages 1 and 2 exhibit hyperphosphatemia, the prevalence increases in CKD stage 3b and becomes incrementally higher in stages 4 (∼20%) and 5 (∼40%). By the time a patient receives dialysis, they are highly likely to be hyperphosphatemic. 

 Hyperphosphatemia Market Epidemiology Segmentation

 

  •  Hyperphosphatemia Market total diagnosed cases 
  •  Hyperphosphatemia Market total prevalent cases 
  •  Hyperphosphatemia Market total stage-specific distribution 

Hyperphosphatemia Market Market Outlook 

The Hyperphosphatemia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hyperphosphatemia market trends by analyzing the impact of current Hyperphosphatemia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of Hyperphosphatemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hyperphosphatemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Hyperphosphatemia market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @ Hyperphosphatemia Market

Hyperphosphatemia Market Key Companies

  • Ardelyx
  • Shield Therapeutics
  • And others.

Hyperphosphatemia Market Therapies

  • Ibsrela (tenapanor)
  • PT20
  • And others.

 

Table of Contents

  1.  Key Insights 
  2.  Report Introduction 
  3.  Executive Summary of Hyperphosphatemia Market 
  4.  Disease Background and Overview
  5.  Epidemiology and patient population
  6.  The United States 
  7.  EU 5
  8.  Hyperphosphatemia Market   Emerging Therapies
  9. Hyperphosphatemia Market Market Outlook
  10.  Market Access and Reimbursement of Therapies
  11.  Appendix
  12.  Hyperphosphatemia Market Report Methodology
  13. DelveInsight Capabilities
  14. Disclaimer

Click here to read more about Hyperphosphatemia Market

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/